Johnson & Johnson (JNJ)vsAlaunos Therapeutics Inc (TCRT)
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
TCRT
Alaunos Therapeutics Inc
$1.60
-1.84%
HEALTHCARE · Cap: $5.99M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3311166433% more annual revenue ($99.33B vs $3,000). JNJ leads profitability with a 16.2% profit margin vs 0.0%. TCRT appears more attractively valued with a PEG of 0.58. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
TCRT
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Growing faster than its price suggests
Areas to Watch
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bull Case : TCRT
The strongest argument for TCRT centers on PEG Ratio. PEG of 0.58 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Bear Case : TCRT
The primary concerns for TCRT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TCRT is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.20 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 24/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Alaunos Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?